In September 2003, Gala Biotech Inc was acquired by Cardinal Health, Inc. (NYSE: CAH), Gala had been developing novel transgenic animal technologies for expression of proteins in milk. The firm had established technologies surrounding gene insertion and the production of pharmaceutical proteins, which became GPEx Technology. The technology was extended to meet the needs of early pharmaceutical development and screening proteins identified through the genome sequencing effort. Gala Biotech developed an innovative portfolio of proprietary protein expression technologies in mammalian cells. These systems have applications ranging from early development protein screening to large-scale pharmaceutical manufacturing.
